Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer

Launched by ISTANBUL TRAINING AND RESEARCH HOSPITAL · May 31, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating a new method to help diagnose cancer spread in patients with invasive ductal breast cancer, which is the most common type of invasive breast cancer. The study focuses on measuring certain immune checkpoint molecules found in fluid taken from lymph nodes that may have cancer. These molecules are important because they could help doctors determine if cancer has spread to these lymph nodes more quickly and easily than current methods. The researchers are looking to see if this washout method, which is similar to techniques used in other cancers, can improve the accuracy of diagnosing cancer spread in breast cancer patients.

To participate in this trial, women aged 65 to 74 who have been diagnosed with invasive ductal carcinoma and are planning to receive neoadjuvant therapy (treatment given before surgery) may be eligible. However, patients with a negative biopsy result for the suspected cancerous lymph node or a positive result in a presumed healthy lymph node, as well as those who are pregnant, have other cancers, or a history of immune system issues, cannot join. Participants in this study can expect to provide samples of lymph node fluid, which will be analyzed to see if the immune markers can help detect cancer spread more effectively. Overall, this research aims to enhance cancer diagnosis, potentially leading to better treatment outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Histopathologically proven invasive ductal carcinoma
• • Patients who will have neoadjuvant therapy
• Exclusion Criteria:
• • The fine-needle aspiration biopsy (FNAB) result of the suspected metastatic lymph node is negative.
• • The FNAB result of the presumed healthy lymph node is malignant.
• • They refuse to participate in the study.
• • They have another primary malignancy.
• • They are pregnant.
• • They have a history of immunodeficiency.